...
首页> 外文期刊>Journal of biomedical nanotechnology >Effective Gene Silencing Mediated by Polypeptide Nanoparticles LAH4-L1-siMDR1 in Multi-Drug Resistant Human Breast Cancer
【24h】

Effective Gene Silencing Mediated by Polypeptide Nanoparticles LAH4-L1-siMDR1 in Multi-Drug Resistant Human Breast Cancer

机译:多肽纳米颗粒LaH4-L1-SIMDR1介导的有效基因沉默在多毒性人乳腺癌中

获取原文
获取原文并翻译 | 示例
           

摘要

MDR (multi-drug resistance) is a major obstacle to the successful treatment of cancers. The combination therapeutic based on RNAi has been investigated as a potential strategy for reversing the MDR. However, the effective delivery of siRNA in vivo remains the challenge for the reality of these candidate RNAi drugs. Cationic peptides for gene delivery have attracted considerable attention due to their biocompatibility and high safety. Herein, self-assembled polypeptide nanoparticles LAH4-L1-siRNA (PNLS) were prepared and loaded with a siRNA (siMDR1) for overcoming MDR in human breast cancer MCF-7/ADR cells in vitro and in vivo. Owing to its cationic charges and alpha-helical conformation, the histidine-rich peptide enhanced cellular uptake of siRNA and represented high gene silencing efficiency. The cellular uptake pathways and internalization process of PNLS into cells were further investigated. In vivo biodistribution indicated that the PNLS exhibited higher tumor-targeted delivery. More importantly, PNLS combined with PTX (Paclitaxel) showed antitumor effects and high MDR1 gene silencing efficiency in the tumor-bearing nude mice. Overall, the PNLS achieved the genetargeted knockdown in vivo and hold immense promise for a new therapeutic drug for breast cancer treatment.
机译:MDR(多药抵抗)是成功治疗癌症的主要障碍。基于RNAi的组合治疗方法被调查为扭转MDR的潜在策略。然而,体内siRNA的有效递送仍然是这些候选RNAi药物现实的挑战。由于其生物相容性和高安全性,基因递送的阳离子肽引起了相当大的关注。这里,制备自组装的多肽纳米颗粒LaH4-L1-siRNA(PNL)并用siRNA(SIMDR1)加载用于在体外和体内克服人乳腺癌MCF-7 / ADR细胞中的MDR。由于其阳离子电荷和α-螺旋构象,富含组氨酸的肽增强了siRNA的细胞吸收,并且代表了高基因沉默效率。进一步研究了PNL进入细胞的细胞摄取途径和内化过程。体内生物分布表明,PNL表现出更高的肿瘤靶向递送。更重要的是,PNL与PTX(紫杉醇)结合在肿瘤裸鼠中显示出抗肿瘤效应和高MDR1基因沉默效率。总体而言,PNL达到了体内基因瘫痪的敲低,并对乳腺癌治疗的新治疗药进行了巨大的承诺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号